Immunotherapy for Lung Malignancies

Slides:

Advertisements

Similar presentations

Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model Licun Wu, MD, Zhihong.

Advertisements

Volume 101, Issue 4, Pages (April 1992)

Treatment of Malignant Pleural Effusion

Volume 153, Issue 5, Pages e93-e96 (May 2018)

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

Diagnostic Surgical Pathology in Lung Cancer

Treating Flu with Skin of Frog

The Therapeutic Potential of Hyaluronan in COPD

Volume 153, Issue 4, Pages (April 2018)

Hiren J. Mehta, MD, Tan-Lucien Mohammed, MD, Michael A. Jantz, MD

Volume 140, Issue 2, Pages e1 (February 2011)

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

Volume 153, Issue 5, Pages (May 2018)

Heavy Metal Enlightens Tumor Immunity

Volume 9, Issue 6, Pages (June 2006)

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Precision Medicine Urgency

Volume 150, Issue 6, Pages (December 2016)

Volume 46, Issue 2, Pages (February 2017)

Tailor-Made Renal Cell Carcinoma Vaccines

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer Takahiro Karasaki, MD, Kazuhiro Nagayama,

Applications of Immunogenomics to Cancer

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Volume 9, Issue 6, Pages (June 2006)

Pilot Study of 1650-G: A Simplified Cellular Vaccine for Lung Cancer

Apnea in the Nonobese CHEST Volume 153, Issue 4, (April 2018)

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

An Elderly Man With Dyspnea and Chest Pain

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Volume 26, Issue 2, Pages (February 2018)

Volume 3, Issue 4, Pages (April 2003)

Optimizing Sleep in the Military

Imaging for the Management of Community-Acquired Pneumonia

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis Fraser J.H. Brims, MD, Tarek M. Meniawy,

Volume 25, Issue 1, Pages (January 2014)

Viperin−/−mice have an increased IFNγ Th1 response.

Volume 23, Issue 10, Pages (October 2015)

Prospective Study on Functional Results After Lung-Sparing Radical Pleurectomy in the Management of Malignant Pleural Mesothelioma Servet Bölükbas, MD,

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Lymphatic Dysfunction Impairs Antigen-Specific Immunization, but Augments Tissue Swelling Following Contact with Allergens Makoto Sugaya, Yoshihiro Kuwano,

Volume 155, Issue 1, Pages (January 2019)

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

Treating Flu with Skin of Frog

Volume 21, Issue 1, Pages (January 2013)

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Required area of lymph node sampling during segmentectomy for clinical stage IA non– small cell lung cancer Hiroaki Nomori, MD, PhD, Yasuomi Ohba, MD,

Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies Francesca L. Nice,

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Volume 92, Issue 1, Pages (July 1987)

Volume 18, Issue 9, Pages (September 2010)

Bedside Calibration Of Pulmonary Artery Catheters

Cormac McCarthy, MD, PhD, Brenna Carey, PhD, Bruce C. Trapnell, MD

Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti, S. Carrara,

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

Mads Hald Andersen, Jürgen C. Becker, Per thor Straten

Volume 8, Issue 2, Pages (August 2003)

Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL Sandra K. Klimuk, Hossain M. Najar,

Volume 24, Issue 6, Pages (June 2016)

POINT: Should Inhaled Antibiotic Therapy Be Used Routinely for the Treatment of Bacterial Lower Respiratory Tract Infections in the ICU Setting? Yes

Volume 20, Issue 3, Pages (March 2012)

Lung Density in Extremely Large Healthy Lungs

Volume 88, Issue 6, Pages (December 2015)

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

Fig. 1 Cancer exome–based identification of neoantigens.

In This Issue Cell Volume 145, Issue 3, (April 2011)

A phase II single-institution study of neoadjuvant stage IIIA/B chemotherapy and radiochemotherapy in non-small cell lung cancer Andreas Granetzny, MD,

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Volume 3, Issue 4, Pages (April 2003)

Presentation transcript:

Immunotherapy for Lung Malignancies Jonathan Chee, PhD, Bruce W.S. Robinson, MD, Robert A. Holt, PhD, Jenette Creaney, PhD CHEST Volume 151, Issue 4, Pages 891-897 (April 2017) DOI: 10.1016/j.chest.2016.10.007 Copyright © 2016 University of Western Australia Terms and Conditions

Figure 1 Tracking neoantigen-specific immune responses by enzyme-linked ImmunoSpot (ELISPOT). Representative picture of ELISPOT wells with spots that represent cells that produce interferon-γ in response to neoantigen peptide stimulation but not to the wild-type peptide sequence. Cells from tumor draining lymph nodes of five mice inoculated with the AB1-HA mesothelioma cell line were tested against predicted neoantigen-peptide-mutated Uqcrc2 (abbreviated to Uq2) and compared against wild-type Uqcrc2 peptide (left). Spots in each well are cells that respond to peptide stimulation. A dot plot quantifying the proportions of spot forming units in each well is shown on the right. MUT = mutant; WT = wild type. CHEST 2017 151, 891-897DOI: (10.1016/j.chest.2016.10.007) Copyright © 2016 University of Western Australia Terms and Conditions

Figure 2 Neoantigen immunotherapy in patients. Tumor samples from patients are sequenced for mutations and have their neoantigens predicted. Neoantigen peptides are synthesized for vaccination. Enzyme-linked ImmunoSpot (ELISPOT) and multimers are used to validate neoantigen T-cell responses in patients' blood. Once validated, T-cell responses in blood can be monitored longitudinally after different immunotherapies, vaccination, or chemotherapy and correlated with clinical outcomes. CHEST 2017 151, 891-897DOI: (10.1016/j.chest.2016.10.007) Copyright © 2016 University of Western Australia Terms and Conditions